Pharmaceutical composition for treating phthisis as well as preparation method and application thereof

Abstract

The invention discloses a pharmaceutical composition for treating phthisis. The pharmaceutical composition consists of the following raw materials in parts by weight: 10-80 parts of ternate buttercup root, 8-60 parts of the tuber of stemona, 8-60 parts of radix asparagi, 5-50 parts of gecko, 3-40 parts of Panax notoginseng, 8-60 parts of rhizoma bletillae, 3-40 parts of bulbus fritillariae cirrhosae, 8-60 parts of radix glehniae, 8-60 parts of bryozoatum, 8-60 parts of radices trichosanthis, 5-50 parts of human placenta and 5-50 parts of donkey-hide gelatin. The invention also discloses a preparation method and an application of the pharmaceutical composition. The pharmaceutical composition disclosed by the invention is simple in composition and novel in formula and has the characteristics of low cost, good curative effect, zero toxic or side effect, difficulty in tolerance, convenience to take and carry and universality for patients suffering from phthisis.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating pulmonary tuberculosis and a preparation method thereof. Background technique [0002] Tuberculosis is a chronic infectious disease that seriously endangers human life and health and restricts economic development. Since the anti-tuberculosis drugs came out one after another in 1944, people's vigilance against it has declined. With the widespread use of anti-tuberculosis drugs, the drug resistance of Mycobacterium tuberculosis is also increasing. Before the 1990s, the new drug-resistant tuberculosis of tuberculosis was less than 5% in the world, and then the incidence increased year by year. The "Global Tuberculosis Control Report" published by WHO in 2007 showed that MDR-TB was found in 37 countries and regions around the world. TB disease, WHO reported in 2008 that the total drug resistance rate of tuberculosis (resistance to at least one drug) ranged from 0 (Andorra) to 57.1% (Kaza...

AI Technical Summary

Problems solved by technology

Chinese patent 201010274878.6 discloses a drug for the treatment of pulmonary tuberculosis. Composed of Campanulaceae, Arrowhead Mushroom, Radix Paeoniae Alba, Clover, and Adenophora; Chinese patent 201210211644.6 discloses a traditional Chinese medicine for the treatment of tuberculosis. , Prunella vulgaris, Bellflower, Amomum, almond; Chinese patent 201310532331.5 discloses a traditional Chinese medicine for the treatment of tuberculosis, the traditional Chinese medicine is composed of Radix Arrhea, Tangerine Peel, Baibu, Almond, Habitat, Ophiopogon japonicus, Sangpi, Pinellia, Anemarrhena Chinese patent 201410144321.9 discloses an oral drug for the treatment of pulmonary tuberculosis, which consists of Dendrobium candidum, Panax ginseng, Dasiwa, Daji, Chuanbeimu, Wuzhimao, Asparagus, Shixiantao , Baiji, Auspicious Grass, Ophiopogon japonicus, Pulmonaria, Dendrobium, Panlong Ginseng, Polygonatum, Spotted Orchid, Zijinniu, Platycodon grandiflorum; the above-mentioned patented formulas have different degrees of therapeutic effect on tuberculosis, but the above-mentioned formulas have different effects on tuberculosis. Patients with pulmonary tuberculosis with low immunity or prominent pain symptoms have poor curative effect. None of the above formulas can regulate immune function or directly treat pain.

The initial original formula is composed of asparagus, steamed basil, Ziheche, donkey-hide gelatin, bletilla, trichosanthin, northern sand ginseng, gecko, notoginseng powder, cat's claw, sea pumice, raw Burnet, madder, sealwort, and has clinical For research materials, see: "Ye Pinliang, Lu Runsheng, Huang Xiushen, etc. 69 cases of pulmonary tuberculosis treated by Feilaokang [J]. Jiangxi Traditional Chinese Medicine, 2009, 40(2):33." However, there are relatively many drugs in this formula, and it is difficult to control the impurity content in the process of large-scale industrial production. Therefore, it is necessary to extensively screen the original formula, split and simplify it, in order to find out less drugs and lower cost. New drug formulations with controllable quality and good clinical efficacy against drug-resistant tuberculosis

Images